BSE filing, NSE: KABRADG. Summary written from the filing by ALFA Finder's alert engine.
Kabra Drugs Ltd: key numbers
- Share price
- ₹16.26
- Market cap
- ₹38.55 Cr
- Revenue (annual)
- ₹92.74 Cr
- Net profit (annual)
- ₹4.96 Cr
- P/E (TTM)
- 5.1×Sector 46.1×
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Kabra Drugs Ltd
All →Kabra Drugs Other Announcement
The company has filed its quarterly shareholding pattern for the period ending September 30, 2026. The document discloses the distribution of shareholding among various categories of investors.
Kabra Drugs Annual General Meeting
Aanjaay Industries Limited conducted its 37th Annual General Meeting on September 30, 2026. Shareholders transacted business including the adoption of financial statements and director appointments.
Kabra Drugs Annual Report
Aanjaay Industries Ltd has submitted its Annual Report for FY 2025-2026 and issued notice for its 37th AGM scheduled for 30th September 2026.
Kabra Drugs Annual General Meeting
Aanjaay Industries Limited announced book closure dates from September 24th to September 30th, 2026, for its Annual General Meeting scheduled for September 30th, 2026.
Kabra Drugs Board Meeting Outcome
Aanjaay Industries Limited announced the notice for its 37th Annual General Meeting and approved board agenda items, including the appointment of directors and auditors.
Kabra Drugs Other Announcement
Aanjaay Industries Limited has shifted its registered office from Indore, Madhya Pradesh, to Chennai, Tamil Nadu, effective August 28, 2026.
Other other announcement announcements
All →Mahindra & Mahindra Financial Services Other Announcement
Mahindra & Mahindra Financial filed its ALM statement as of September 30, 2026, submitted to RBI. It is a periodic regulatory return with no new transaction.
ACME Solar Holdings Other Announcement
ACME Solar filed the CARE Ratings monitoring agency report on its Rs.2,800 crore QIP for the quarter ended 30 September 2026. The report shows no deviation from the offer objects.
eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.